3
Participants
Start Date
July 31, 2015
Primary Completion Date
December 31, 2015
Study Completion Date
December 31, 2015
rFVIIIFc
As described in the treatment arm
rFIXFc
As described in the treatment arm
non-Fc FVIII replacement products
Standard plasma-derived (pd) or recombinant (r) FVIII concentrate and other traditional treatment options
non-Fc FIX replacement products
Standard plasma-derived (pd) or recombinant (r) FIX concentrate and other traditional treatment options
Research Site, East Lansing
Research Site, Los Angeles
Lead Sponsor
Collaborators (1)
Swedish Orphan Biovitrum
INDUSTRY
Bioverativ Therapeutics Inc.
INDUSTRY